885272-94-6

Basic information

• Product Name: Ethyl 6-bromo-1H-indazole-3-carboxylate
• Synonyms: 6-BroMo-1H-indazole-3-carboxyile acid ethyl ester;1H-Indazole-3-carboxylic acid, 6-broMo-, ethyl ester
• CAS NO: 885272-94-6
• Molecular Formula: C₁₀H₉BrN₂O₂
• Molecular Weight: 269.09
• Mol File: 885272-94-6.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 406.4 °C at 760 mmHg
• Flash Point: 199.6 °C
• Appearance: /
• Density: 1.624 g/cm³
• Vapor Pressure: 8.15E-07mmHg at 25°C
• Refractive Index: 1.653
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: Ethyl 6-bromo-1H-indazole-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 6-bromo-1H-indazole-3-carboxylate(885272-94-6)
• EPA Substance Registry System: Ethyl 6-bromo-1H-indazole-3-carboxylate(885272-94-6)

Safety Data

• Hazardous Substances Data: 885272-94-6(Hazardous Substances Data)

Usage

General Description

Ethyl 6-bromo-1H-indazole-3-carboxylate is a chemical compound with the molecular formula C10H10BrN2O2. It is a derivative of indazole, which is a heterocyclic aromatic organic compound. This chemical contains an ethyl group, a bromine atom, and a carboxylic ester functional group attached to the indazole ring structure. It is commonly used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and other fine chemicals. The presence of the bromine atom in the molecule makes it useful for various organic reactions, such as nucleophilic substitution and palladium-catalyzed coupling reactions. Ethyl 6-bromo-1H-indazole-3-carboxylate has applications in medicinal chemistry and chemical research, particularly in the development of new drugs and bioactive compounds.

InChI:InChI=1/C10H9BrN2O2/c1-2-15-10(14)9-7-4-3-6(11)5-8(7)12-13-9/h3-5H,2H2,1H3,(H,12,13)

Upstream product

• 6326-79-0 6-bromoisatin 
• 660823-36-9 6-bromo-1H-indazole-3-carboxylic acid 
• 64-17-5 ethanol 

Downstream Products

• 1228451-61-3 1-tert-butyl 3-ethyl-6-(4-nitrophenyl)-1H-indazole-1,3-dicarboxylate 
• 1228450-05-2 ethyl 6-(4-aminophenyl)-1H-indazole-3-carboxylate 
• 1228450-07-4 ethyl 6-(4-(3-(trifluoromethyl)benzamido)phenyl)-1H-indazole-3-carboxylate 
• 1228450-38-1 ethyl 6-(4-(3-(3,4-dichlorophenyl)ureido)phenyl)-1H-indazole-3-carboxylate 
• 1228451-63-5 6-(4-(3-(trifluoromethyl)benzamido)phenyl)-1H-indazole-3-carboxylic acid 
• 1228450-43-8 N-methyl-6-(4-(3-(trifluoromethyl)benzamido)phenyl)-1H-indazole-3-carboxamide 
• 1228450-53-0 N-(2-morpholinoethyl)-6-(4-(3-(trifluoromethyl)benzamido)phenyl)-1H-indazole-3-carboxamide 
• 1228451-65-7 6-(4-nitrophenyl)-1H-indazole-3-carboxylic acid 
• 1228451-67-9 N-methyl-6-(4-nitrophenyl)-1H-indazole-3-carboxamide 
• 1228451-69-1 6-(4-aminophenyl)-N-methyl-1H-indazole-3-carboxamide 
• 1228450-67-6 N-methyl-6-(4-(pyridazine-4-carboxamido)phenyl)-1H-indazole-3-carboxamide 
• 885279-19-6 6-cyano-1H-indazole-3-carboxylic acid ethyl ester 

Relevant articles and documents

Pyrazolopyridine or indazole derivatives as protein kinase inhibitors

The present invention relates to novel pyrazolopyridine or indazole derivatives having inhibitory activity against protein kinases or pharmaceutically acceptable salts thereof. Since compounds of the present invention have excellent inhibitory activity against to protein kinases, for example, ABL, ACK1, ALK, Aurora A, Aurora B, Aurora C, BLK, BMX/ETK, BRSK1, BTK, c-Src, CAMKK, CDK1, CDK2, CDK5, CLK, DDR, DYRK1B, EPHA, EPHB, FAK/PTK2, FER, FES/FPS, FGFR, FGR, FLT3, FLT4/VEGFR3, FMS, FRK/PTK5, FYN, GSK3b, HCK, IGF1R, IR, IRAK1, IRR/INSRR, ITK, JAK2, KHS/MAP4K5, LCK, LYN, PHKg, PLK4/SAK, PYK2, RET, ROS/ROS1, TIE2/TEK, TRK, TXK, TYK, YES/YES1, and the like, the compounds are useful for treatment and prevention of various kinds of cancer diseases.

NOVEL INDAZOLE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS PROTEIN KINASE INHIBITORS FOR PROLIFERATIVE DISEASES TREATMENT, AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT

Disclosed are novel indazole derivatives represented by the following Chemical Formula 1 or pharmaceutically acceptable salts, hydrates or solvates thereof, and pharmaceutical compositions for the prevention or treatment of proliferative diseases, containing the same as an active ingredient. Having potent inhibitory effect against protein kinase, such as b-raf, KDR, Fms, Tie2, SAPK2a and Ret, inducing diseases caused by abnormal cell proliferation, the novel indazole derivatives can be used for the prevention or treatment of diseases caused by abnormal cell proliferation.